Pociredir

DRUG2 trials

Sponsors

Fulcrum Therapeutics

Conditions

Sickle Cell Disease

Phase 1

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

TerminatedNCT07431398

Fulcrum TherapeuticsSickle Cell Disease

Start: 2025-12-13End: 2026-06-01Updated: 2026-06-18

Phase 2

Open-Label Extension Study to Pioneer Study 6058-SCD-101

Enrolling by invitationNCT07401823

Fulcrum TherapeuticsSickle Cell Disease

Start: 2026-03-30End: 2030-07-05Target: 50Updated: 2026-04-14